Key result
Contrast-medium administration resulted in a monotonic increase in skeletal muscle area and a significant decrease in visceral adipose tissue area (up to -23.7%), with strong correlations between L3 and L1 measurement levels.
Why the study?
CT-derived body composition parameters are promising prognostic factors, but the effects of contrast-medium administration and measurement level (L3 vs L1) needed comprehensive evaluation.
How do contrast-medium administration and vertebral measurement level affect computed tomography-derived body composition parameters?
Observational (n=203)
No
How do contrast-medium administration and vertebral measurement level affect computed tomography-derived body composition parameters?
p-value: p=<0.001
CT-derived body composition parameters vary significantly across contrast phases but show strong correlation between L1 and L3 levels, allowing for interchangeability in cohorts with mixed CT conditions.
Contrast phase and vertebral level alter CT body composition metrics; leaves open standardization needs before prognostic use in practice or trials.
Objective To comprehensively evaluate the effects of contrast-medium administration and measurement level (L3 and L1) on computed tomography (CT) derived body composition parameters, promising prognostic factors for various diseases. Methods 203 dynamic contrast-enhanced CT examinations, including unenhanced (phase 0) and early arterial, late arterial, portal, and equilibrium phases (phases 1-4, respectively), were retrospectively enrolled in the study. Areas and mean densities of skeletal muscle (SMA and MSMD), subcutaneous adipose tissue (SATA and MSATD), and visceral adipose tissue (VATA and MVATD) were measured at L3 and L1 levels across five phases (phase 0–4). Measurement changes among phases and levels were assessed statistically. Results The rates of SMA, SATA, and VATA on phase 1/2/3/4 compared to those on phase 0 were as follows: L3 SMA +1.1%/+2.1%/+2.8%/+3.5%; L1 SMA, +2.0%/+2.7%/+3.0%/+3.7%; L3 SATA −0.4%/−1.9%/−2.9%/−4.7%; L1 SATA −0.3%/−2.2%/−3.5%/−6.1%; L3 VATA −7.5%/−17.8%/−20.0%/−22.2%; L1 VATA −8.5%/−20.1%/−22.6%/−23.7%. Differences of MSMD, MSATD, and MVATD on phase 1/2/3/4 between those on phase 0 were as follows (Hounsfield Units): L3 MSMD, +2.1/+5.8/+7.8/+9.6; L1 MSMD, +2.9/+7.7/+9.1/+9.8; L3 MSATD, +1.2/+3.7/+4.8/+6.2; L1 MSATD, +1.2/+3.8/+4.7/+5.6; L3 MVATD, +1.5/+4.1/+5.2/+6.1; L1 MVATD, +1.9/+4.9/+5.8/+6.3. The values between L3 and L1 showed a linear solid correlation (coefficient of determination, 0.950–0.999), suggesting interchangeability. Conclusion Changes in body composition parameters measured in various contrast phases and two dominant body levels were comprehensively elucidated, promoting the interchangeability of cohorts with mixed CT conditions.
No takes yet. Share an insight, caveat, or question.
Akamatsu et al. (2024) conducted an observational in Hepatobiliary diseases (n=203). Contrast-medium administration and post-contrast timing vs. Unenhanced CT (phase 0) was evaluated on Changes in CT-derived body composition parameters (SMA, SATA, VATA) across contrast phases (p=<0.001). Contrast-medium administration resulted in a monotonic increase in skeletal muscle area and a significant decrease in visceral adipose tissue area (up to -23.7%), with strong correlations between L3 and L1 measurement levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: